Rebeccamycin: Difference between revisions
m (Protected "Rebeccamycin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
Line 16: | Line 16: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 29: | Line 29: | ||
</div> | </div> | ||
[[Category:Chemotherapeutic agents]] | [[Category:Chemotherapeutic agents]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Latest revision as of 15:34, 20 August 2012
File:Rebeccamycin.png | |
Identifiers | |
---|---|
| |
CAS Number | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C27H21Cl2N3O7 |
Molar mass | 570.38 |
WikiDoc Resources for Rebeccamycin |
Articles |
---|
Most recent articles on Rebeccamycin Most cited articles on Rebeccamycin |
Media |
Powerpoint slides on Rebeccamycin |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Rebeccamycin at Clinical Trials.gov Clinical Trials on Rebeccamycin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Rebeccamycin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Rebeccamycin Discussion groups on Rebeccamycin Patient Handouts on Rebeccamycin Directions to Hospitals Treating Rebeccamycin Risk calculators and risk factors for Rebeccamycin
|
Healthcare Provider Resources |
Causes & Risk Factors for Rebeccamycin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Rebeccamycin is a weak topoisomerase I inhibitor isolated from Streptomyces sp. structurally similar to staurosporine. Does not show any inhibitory activity against protein kinases. Shows significant antitumor properties in vitro (IC50=480nM against mouse B16 melanoma cells and IC50=500nM against P388 leukemia cells).
References
- Production and biological activity of rebeccamycin, a novel antitumor agent: J.A. Bush, et al.; J. Antibiot. (Tokyo) 40, 668 (1987)
- Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group F. Anizon, et al.; J. Med. Chem. 40, 3456 (1997)
- DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin: C. Bailly, et al.; Biochemistry 36, 3917 (1997)
- Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition: C. Bailly, et al.; Chem. Biol. 6, 277 (1999)
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Chemotherapeutic agents